Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used medications worldwide [1, 2] . More than 30 million NSAIDs are prescribed every day in the United States [2] and they are also widely available as an over-the-counter medication. The efficacies of their anti-inflammatory and analgesic effects are well-established [3] and NSAIDs are recommended in the management of rheumatic diseases such as rheumatoid arthritis (RA) [4] and osteoarthritis (OA) [5] [6] [7] .
Despite the recognised benefits and availability of NSAIDs, they are also known to cause Background: Non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (GI) adverse events are well-described in the Western population but data is lacking in Asian patients. This study aims to describe the incidence and predictive factors for NSAID-induced upper GI complications in a cohort of multi-ethnic patients in Malaysia.
Methods and Findings: A retrospective cohort study was conducted in adult patients with rheumatoid arthritis (RA) and/or osteoarthritis (OA) from 2010-2013 in four main rheumatology centres in Malaysia with computerized clinical and pharmaceutical records. Clinical, pharmaceutical and demographic data over a 24-months follow-up period were analysed in subjects who were prescribed long-term NSAID therapy (defined as a minimum duration of four weeks). 634 patients were included in the final analysis with the following characteristics: mean age 53.4 ± 12.5 years, 89.9% female, diagnosis: RA 59.5%, OA 10.2% and RA/OA combination 30.3%. 371 (58.5%) patients received non-selective NSAIDs and 263 (41.5%) patients received COX-2 inhibitors. There were a total of 84 GI adverse events during the period of study, giving an incidence rate of 66.2 per 1000 person-years and a risk of 13.2%. The majority of upper GI adverse events was dyspepsia (92.9%), and only 7.1% with peptic ulcer disease/ upper GI bleeding. Multivariate analysis showed that the only independent predictive factor of upper GI adverse event in this cohort was a history of upper GI disease (O.R. 2.073, 95% C.I. 1.029 -4.176). COX-2 inhibitor showed a trend towards, but not independently predictive of, GI protection in this analysis (OR 0.643; 95% C.I. 0.397 -1.043).
a spectrum of adverse events involving the gastrointestinal (GI), cardiovascular and renal systems. The most common of these adverse events are gastrointestinal, with a reported prevalence of 15-36.7% for dyspepsia [8] [9] [10] , 4.36-6.19% for peptic ulcer disease (PUD) [11] and 0.21-3.6% for upper GI bleeding (UGIB) [11, 12] . These adverse events have important clinical implications, contributing to patient morbidity, mortality and increased healthcare utilisation and costs.
One of the strategies to limit these adverse events includes identifying predictive factors for these adverse events among long-term NSAID users. Established GI risk factors include age ≥ 65 years [13] , upper GI history [14] , concomitant medications (e.g. prednisone, aspirin, nonaspirin anti-platelet and anticoagulant) [15, 16] and H. pylori infection [17] . It is crucial for the prescribing clinician to identify high-risk patients, in whom specific options can be clinically beneficial and cost-effective, such as prescribing more GI-favourable COX-2 specific inhibitor versus traditional NSAID, adding a GI protective agent (e.g. proton pump inhibitor) or avoiding NSAIDs altogether. There is a paucity of information in Asian patients on long-term NSAID therapy. A previous community-based survey in Malaysia has revealed that over-thecounter purchases for NSAIDs for prolonged duration were not uncommon [18] . Another study from Northern Malaysia revealed that 35,944 prescriptions for NSAIDs per 100,000 patients were administered annually from a single institution [19] , indicating the common usage of NSAIDs among Asians.
As NSAIDs are commonly prescribed on a long-term basis for patients with chronic rheumatological conditions, this study aimed to identify the incidence and predictive factors of NSAID-induced upper GI adverse events in Malaysian patients with chronic rheumatic diseases.
Methods

Study population
A retrospective, multi-centre, cohort study was conducted at four large public hospitals with rheumatology units in the Klang Valley, an area with the highest population density in Malaysia of almost 7 million people [20] .
Study protocol
Electronic prescription data in the respective hospitals were accessed to determine long-term NSAID users (defined as at least four weeks prescriptions of any type of NSAID) among patients diagnosed with RA and/or OA who were on active rheumatology clinic follow up in 2010 or 2011 in the four hospitals. These patients were followed up for 24 months via manual review of the medical records to determine whether any upper GI adverse event(s) developed in the 24 months follow up period. The exclusion criteria were incomplete prescription data, patients who defaulted follow-up and GI adverse event within 6 months prior to recruitment in the study.
Data collection
Data analysis
Data was analysed using the Statistical Package of Social Sciences (SPSS) version 23. Descriptive statistics was used for demographic data analysis and frequencies of each type of GI adverse events. The incidence rate (per 1000 person-years) was calculated using the formula=(number of new cases of upper GI adverse events × 1000)/(total number of RA/OA patients observed × 2 years of observation). Each concomitant medication (prednisone, aspirin, non-aspirin anti-platelet and anticoagulant) was considered an individual GI risk factor (one point each) in the analysis. Pearson chi-square test was used to determine significant associations for categorical variables with a p-value of <0.05 indicating statistical significance. The odds ratio for the calculation of risk of upper GI events was determined using logistic regression for the multivariate test.
Results
1679 patients with an RA and/or OA diagnosis on regular rheumatology clinic follow up in 2010 or 2011 at the four hospitals were screened. 634 of these patients received long-term NSAID therapy and the medical records of these patients were followed up for 24 months from the date of the NSAID prescription.
Demographic data
The demographic data of the included patients (N=634) are described in Table 1 . Their mean age was 53.4 ± 12.5 years and the majority of patients (83.0%) were under the age of 65 years. Most patients were female (89.9%). Almost half of the patients (45.1%) were on concomitant prednisone, while aspirin was concomitantly prescribed in only 8.1% of patients. A small proportion of patients were on other antiplatelet agents (1.7%) and anticoagulants (1.3%). 88.5% of patients had no history of upper GI disease and there were no patients with a history of upper gastrointestinal bleeding. We determined that 371 (58.5%) of the 634 patients received NSAIDs prior to the start of the 24 months follow-up in this study. There were 371 (58.5%) patients in the non-selective NSAIDs group, comprising of 267 patients who received nonselective NSAIDs and 104 patients who received combination of non-selective and COX-2 inhibitors. 263 (41.5%) patients were prescribed only COX-2 inhibitors.
Incidence of upper GI adverse events
A total of 84 upper GI adverse events occurred during the 24 months follow up, translating to an incidence of 66.2 per 1000 person-years and a risk of 13.2%. These upper GI adverse events consisted of 78 patients with dyspepsia, five patients with PUD and one patient with upper GI bleeding.
Upper GI adverse events were higher in the COX-2 group (43/263, 16.3%) compared to the non-selective NSAID group (41/371, 11.1%) but this did not reach statistical significance (Chi-square p=0.053). 16 (39.0%) of the 41 patients with upper GI adverse events in the non-selective NSAID group took a combination of selective and non-selective NSAIDs in the 24 months follow up period.
Predictive factors of upper GI adverse events
Univariate analysis Table 2 revealed that variables that were associated with upper GI adverse events were a gastrointestinal history, number of GI risk factors (0 and 1-2 risk factors) and GI prophylaxis. The type of NSAID, 3-4 GI risk factors and concomitant prednisone did not reach statistical significance in this analysis. Age group and concomitant aspirin were not associated with upper GI adverse events. There was no significant difference in upper GI adverse events when comparing the type of rheumatic disease (RA/RA with OA vs. OA alone).
Multivariate analysis, analysed using logistic regression analysis Table 3 , subsequently revealed that a previous history of upper GI disease (OR 2.073, 95% C.I. 1.029-4.176) was independently predictive of GI adverse event. Gender (male), concomitant prednisone and GI [21] was a strong predictor of risk of GI events. A large, prospective, double-blinded GI outcomes trial of 8076 patients with rheumatoid arthritis additionally reported that a history of GI disease increases the risk of GI events by approximately 2-to 4-fold [14] . Furthermore, patients with prior history of NSAID-related dyspepsia have been reported to have an increased risk of ulcer complications (OR 8.7, 95% CI 4.0-18.9) when consuming long-term NSAIDs [22] . However, we are not able to determine whether prior history of NSAID-related dyspepsia was a predictor of upper GI events as the aetiology of prior upper GI disease was not available from the patient's medical records.
Other factors, such as concomitant usage of antiplatelet agents [15, 23, 24] , anti-coagulants [25] [26] [27] and steroids [16, 28, 29] have been shown to increase the risk of NSAID-associated GI complications but these factors were not found to be predictive in this study. We were not able to explore the role of Helicobacter pylori infection [17, 30] or higher doses of NSAIDs [2, 31] and multiple NSAID use [28] , which are recognised causes of NSAID-associated GI complications as this information was not available for all patients in this study.
Although each GI risk factor has different odds or risk ratio for GI adverse events, there is no widely accepted algorithm to aid in quantifying and combining multiple risk factors for upper GI adverse events due to NSAIDs. However, a large randomised double-blinded study of over 34,000 patients [13] showed that the rate of GI events increased with increasing number (0,1,2,3 and 4) of the four major risk factors (age ≥ 65 years, prior upper GI clinical event, low-dose aspirin use and systemic corticosteroid use).
In this study, we combined the number of risk factors in our study into groups of increasing numbers for analysis (0, 1-2 and 3-4 risk factors).
Limitations and Strengths
One of the limitations of this retrospective study was the complete reliance on medical records and as such, some patients may not have reported their GI symptoms during routine clinic visits, thus affecting the true incidence of GI adverse events in this patient population and subsequently further analysis on the predictive factors. Secondly, patients with GI risk factor(s) may have been preferentially prescribed a COX-2 inhibitor or GI prophylaxis, potentially confounding the results of this study. Additionally, only double-dose H2RAs have been shown to reduce upper GI adverse events [9, 32] and all patients prescribed with H2RAs for GI prophylaxis in this study were given standard doses of H2RAs. Another possible confounder is over-the-counter usage of NSAID, which is common among Malaysian adults [18] . It is possible that rheumatic patients prescribed COX-2 inhibitors alone may have additionally consumed non-selective NSAID by purchasing over-the-counter medications. Similarly, our data on patients using GI protective agents may have been inaccurate, as over-the-counter availability and usage of H2RAs and PPIs are also quite common in the local community [33] . Another limitation was the fact that this study was not sufficiently powered to calculate for differences in GI adverse events between classes of NSAID. This may be the reason why COX-2 inhibitors did not significantly confer protection in this study whereas several large randomised clinical trials (CLASS, TARGET and SUCCESS-I) [10, 34, 35] have shown otherwise. For possibly the same reason, GI prophylaxis was not found to be protective in this study, in contrast to the findings of other large studies [32, 36] .
The data in this study is robust for several reasons. Firstly, the upper GI effects in this study have been observed in a uniform group of patients (i.e. patients with rheumatic diseases) and there are unlikely to be other confounders for GI complications in these patients apart from their concomitant treatment for the rheumatic diseases. However, we acknowledge that other minor confounders such as diet, short-term medications (e.g. antibiotics) and alcohol history may have existed. Secondly, the study subjects were fairly representative of most Malaysian patients with rheumatic diseases as the public healthcare system in Malaysia manages the majority of adults with complex, chronic diseases. The Malaysian healthcare system is generally divided into public and privately funded health institutions [37] . Nationally, patients mostly rely on the publicly-funded healthcare system for the management of complex chronic disease. Due to the chronic and costly treatment of rheumatology disorders, particularly RA that often has relatively early onset and peaking at age 30-55 years old [38] , it is estimated that the majority of rheumatology patients in Malaysia are treated within the public healthcare system. Furthermore, there was comprehensive data on all medication prescriptions as this was available electronically in all four centres. Our data may not be representative of patients on longterm NSAID managed in non-referral centres. Nevertheless, this study provides useful clinical information for patients managed in tertiary care referral centres.
Conclusion
The risk of upper GI adverse events in our Malaysian cohort of patients (13.2%) is comparable to the Western population. Prior upper GI disease was the only independent predictive factor identified in this study and the rheumatic patients on long-term NSAIDs with this risk factor were twice as likely to develop further upper GI events. Judicious prescription of NSAIDs in patients with this risk factor is recommended. Future studies that are adequately-powered, suitably-designed and incorporate rheumatology patients in nonreferral centres and primary care are needed to determine the role of COX-2 selective inhibitors and GI protective agents in Asian patients in reducing the risk of upper GI adverse events in Asian patients on long-term NSAID.
Ethics approval
Ethical approval was granted to conduct this research within the following centres:
• University Malaya Medical Centre 
